Study of SXL01 in Patients With Metastatic Castration-Resistant Prostate Cancer (PROSTIRNA)
Status:
Withdrawn
Trial end date:
2020-06-01
Target enrollment:
Participant gender:
Summary
This is a single site, open-label, non-randomized, dose escalation phase I study designed to
evaluate the safety, the tolerability and the Recommended Phase II Dose (RP2D) of SXL01, a
synthetic small interfering ribonucleic acid (RNA) targeting the androgen receptor messenger
RNA (mRNA), in patients with metastatic castration-resistant prostate cancer.
A standard method "3+3" will be used for dose escalation. A maximum of 30 patients will
complete the dose-escalation phase of the study; 12 additional patients will be included at
the RP2D in the expansion phase.